These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9733364)

  • 1. Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs.
    Rebello SS; Huang J; Shiu WJ; Saito K; Kaneko M; Saitoh Y; Lucchesi BR
    J Cardiovasc Pharmacol; 1998 Sep; 32(3):485-94. PubMed ID: 9733364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo efficacy of SM-20302, a GP IIb/IIIa receptor antagonist, correlates with ex vivo platelet inhibition in heparinized blood but not in citrated blood.
    Rebello SS; Huang J; Saito K; Lucchesi BR
    Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):954-60. PubMed ID: 9633937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
    Huang J; Rebello SS; Faul JD; Lucchesi BR
    Pharmacology; 1999 May; 58(5):252-64. PubMed ID: 10087466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic effect of SM-20302, a nonpeptide GPIIb/IIIa antagonist, in a photochemically induced thrombosis model in guinea pigs.
    Horisawa S; Kaneko M; Ikeda Y; Ueki Y; Sakurama T
    Thromb Res; 1999 May; 94(4):227-34. PubMed ID: 10336238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporary and partial inhibition of platelets by SM-20302 prevents coronary artery thrombosis in a chronic canine model.
    Huang J; Rebello SS; Rosenberg LA; Kaneko M; Sakurama T; Lucchesi BR
    Eur J Pharmacol; 1999 Feb; 366(2-3):203-13. PubMed ID: 10082201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel platelet glycoprotein IIB/IIIA receptor antagonist, XU063, in beagle dogs.
    Kapil RP; Emm TA; Mousa SA; Padovani PK; Quon CY; Lam GN
    Thromb Res; 1997 May; 86(3):221-32. PubMed ID: 9175243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pentobarbital on pharmacokinetics and pharmacodynamics of a potent fibrinogen receptor antagonist, L-734,217, in dogs.
    Prueksaritanont T; Stranieri MT; Hand EL; Ellis JD; Holahan MA; Sitko GR; Cook JJ
    Biopharm Drug Dispos; 1997 Nov; 18(8):649-63. PubMed ID: 9373723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists.
    Rebello SS; Huang J; Faul JD; Lucchesi BR
    J Thromb Thrombolysis; 2000 Jan; 9(1):23-8. PubMed ID: 10590185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist.
    Mousa SA; DeGrado WF; Mu DX; Kapil RP; Lucchesi BR; Reilly TM
    Circulation; 1996 Feb; 93(3):537-43. PubMed ID: 8565173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.
    Wittke B; Mackie IJ; Machin SJ; Timm U; Zell M; Goggin T
    Br J Clin Pharmacol; 1999 May; 47(5):521-30. PubMed ID: 10336576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog.
    Rebello SS; Driscoll EM; Lucchesi BR
    Stroke; 1997 Sep; 28(9):1789-96. PubMed ID: 9303027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs.
    Modi NB; Baughman SA; Paasch BD; Celniker A; Smith SY
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):888-97. PubMed ID: 7564333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796.
    Hennan JK; Hong TT; Willens DE; Driscoll EM; Giboulot TA; Lucchesi BR
    Br J Pharmacol; 2002 Jul; 136(6):927-37. PubMed ID: 12110617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist.
    Damiano BP; Mitchell JA; Giardino E; Corcoran T; Haertlein BJ; de Garavilla L; Kauffman JA; Hoekstra WJ; Maryanoff BE; Andrade-Gordon P
    Thromb Res; 2001 Oct; 104(2):113-26. PubMed ID: 11672755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic analysis of TS-943, a selective non-peptide platelet glycoprotein-IIb/IIIa (GPIIb/IIIa) receptor antagonist, using a nonlinear mixed effect model in dogs.
    Furuya A; Nozawa M; Gotoh J; Jingu S; Akimoto M; Higuchi S; Suwa T; Ogata H
    J Pharm Pharmacol; 2002 Jul; 54(7):921-7. PubMed ID: 12162710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802.
    Mousa SA; Olson RE; Bozarth JM; Lorelli W; Forsythe MS; Racanelli A; Gibbs S; Schlingman K; Bozarth T; Kapil R; Wityak J; Sielecki TM; Wexler RR; Thoolen MJ; Slee A; Reilly TM; Anderson PS; Friedman PA
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):169-76. PubMed ID: 9700976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and pharmacodynamics of TS-943 for selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist in normal healthy subjects.
    Furuya A; Kato N; Jingu S; Akimoto M; Higuchi S; Suwa T; Ogata H
    Clin Pharmacol Ther; 2000 May; 67(5):489-97. PubMed ID: 10824627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.